In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

VNUS Medical Technologies, Inc.

http://www.vnus.com

Latest From VNUS Medical Technologies, Inc.

Finance Watch: Two New VC Funds Raise $755m To Fund Innovation

Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.

Financing StartUps and SMEs

Appointments: Gyroscope, Urovant, Horizon, Modus, Allied Minds And Adherium

This week's roundup includes CEO appointments by Gyroscope Therapeutics, Urovant Sciences and Nevoii Pharmaceuticals, in addition to various other high-level appointments by companies including, Horizon Pharma, Veloxis Pharmaceuticals, Modus Therapeutics and Adherium.

Appointments BioPharmaceutical

Medical Device Market & Industry Briefs, April 2012

Brief summaries of recent medtech market and industry developments. This month we cover Covidien’s continuing buying spree, and other medtech M&A.

Medical Device Deals

The A-List: The Trend-Shaping Series A Financings Of 2011

The capital drought that hit life science companies the past three years worked its way upstream in 2011, as several venture firms said they wouldn’t either continue in the life sciences or raise new funds. But our annual tally of life science Series A rounds presents a surprising twist: Series A rounds are up, not in blockbuster numbers by any stretch, but the downward trend of the recession years has finally been reversed. Among the year's nearly 100 Series A rounds we found plenty of oncology and peripheral vascular disease start-ups, as well as big bets on rare disease, along with some considerable nods to emerging markets.

BioPharmaceutical Medical Device
See All

Company Information

UsernamePublicRestriction

Register